12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok

More documents

Recommendations

Info

Sokal index (Kliniske oplysninger fra debuttidspunkt) Thrombocyttal mia/L Miltstørrelse (cm under curvaturen) Procent blaster i perifert blod Alder Klik her for at foretage en automatisk beregning af Sokal index'et. Klik her for at foretage en automatisk beregning af Hasford score: (www.kompetenznetz-leukaemie.de/cgi-bin/pharmacoepi/cmlscore) Referencer vedrørende HCT af CML Prognostiske faktorer Hasford, J., Pfirrmann, M., Hehlmann, R., Allan, N.C., Baccarani, M., Kluin-Nelemans, J.C., Alimena, G., Steegmann, J.L., and Ansari, H. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst, 90: 850-858, 1998. Sokal, J.E., Cox, E.B., Baccarani, M., Tura, S., Gomez, G.A., Robertson, J.E., Tso, C.Y., Braun, T.J., Clarkson, B.D., and Cervantes, F. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood, 63: 789- 799, 1984. Sokal, J.E., Baccarani, M., Tura, S., Fiacchini, M., Cervantes, F., Rozman, C., Gomez, G.A., Galton, D.A., Canellos, G.P., and Braun, T.J. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood, 66: 1352-1357, 1985. Wadhwa, J., Szydlo, R. M., Apperley, J. F., Chase, A., Bua, M., Marin, D., Olavarria, E., Kanfer, E., and Goldman, J. M. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood, 99: 2304-2309, 2002. Behandlingsstrategi Baccarani,M., Cortes,J., Pane,F., Niederwieser,D., Saglio,G., Apperley,J., Cervantes,F., Deininger,M., Gratwohl,A., Guilhot,F., Hochhaus,A., Horowitz,M., Hughes,T., Kantarjian,H., Larson,R., Radich,J., Simonsson,B., Silver,R.T., Goldman,J., & Hehlmann,R. (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J.Clin.Oncol., 27, 6041-6051. Goldman,J.M. (2007) How I treat chronic myeloid leukemia in the imatinib era. Blood, 110, 2828-2837. Shah,N.P. (2007) Medical Management of CML. Hematology.Am.Soc.Hematol.Educ.Program., 2007, 371-375. Branford,S. (2007) Chronic myeloid leukemia: molecular monitoring in clinical practice. Hematology.Am.Soc.Hematol.Educ.Program., 2007, 376-383. Imatinib/STI-571 Druker,B.J., Guilhot,F., O'Brien,S.G., Gathmann,I., Kantarjian,H., Gattermann,N., Deininger,M.W., Silver,R.T., Goldman,J.M., Stone,R.M., Cervantes,F., Hochhaus,A., Powell,B.L., Gabrilove,J.L., Rousselot,P., Reiffers,J., Cornelissen,J.J., Hughes,T., Agis,H., Fischer,T., Verhoef,G., Shepherd,J., Saglio,G., Gratwohl,A., Nielsen,J.L., Radich,J.P., Simonsson,B., Taylor,K., Baccarani,M., So,C., Letvak,L., & Larson,R.A. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N.Engl.J.Med., 355, 2408-2417. 56
Mauro,M.J. (2006) Defining and managing imatinib resistance. Hematology.Am.Soc.Hematol.Educ.Program., 219-225. O'Hare,T., Eide,C.A., & Deininger,M.W. (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood, 110, 2242-2249. Marin, D., et al. "European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor." Blood 112.12 (2008): 4437- 44. Interferonbehandling versus kemoterapi Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. J Natl Cancer Inst, 89: 1616-1620, 1997. Gale, R.P., Hehlmann, R., Zhang, M.J., Hasford, J., Goldman, J.M., Heimpel, H., Hochhaus, A., Klein, J.P., Kolb, H.J., McGlave, P.B., Passweg, J.R., Rowlings, P.A., Sobocinski, K.A., and Horowitz, M.M. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood, 91: 1810-1819, 1998. Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.L., Maloisel, F., Bouabdallah, R., Guyotat, D., Cheron, N., Nicolini, F., Abgrall, J.F., and Tanzer, J. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med, 337 : 223-229, 1997. Interferonbehandling før HCT Morton, A.J., Gooley, T., Hansen, J.A., Appelbaum, F.R., Bruemmer, B., Bjerke, J.W., Clift, R., Martin, P.J., Petersdorf, E.W., Sanders, J.E., Storb, R., Sullivan, K.M., Woolfrey, A., and Anasetti, C. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood, 92: 394-401, 1998. Autolog HCT Bhatia, R., Verfaillie, C.M., Miller, J.S., and McGlave, P.B. Autologous transplantation therapy for chronic myelogenous leukemia. Blood, 89: 2623-2634, 1997. HCT med søskendedonor van Rhee, F., Szydlo, R.M., Hermans, J., Devergie, A., Frassoni, F., Arcese, W., de Witte, T., Kolb, H.J., Niederwiser, D., Jacobsen, N., Gahrton, G., Bandini, G., Carreras, E., Bacigalupo, A., Michallet, M., Ruutu, T., Reiffers, J., Goldman, J.M., Apperley, J., and Gratwohl, A. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant, 20: 553-560, 1997. Radich,J.P., Gooley,T., Bensinger,W., Chauncey,T., Clift,R., Flowers,M., Martin,P., Slattery,J., Sultan,D., & Appelbaum,F.R. (2003) HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood, 102, 31-35. HCT med MUD Davies, S. M., DeFor, T. E., McGlave, P. B., Miller, J. S., Verfaillie, C. M., Wagner, J. E., and Weisdorf, D. J. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am.J.Med., 110: 339-346, 2001. 57
Page 1 and 2:
Rekommandationer for knoglemarvstra
Page 3 and 4:
Vævstyper og terminologi Ved valg
Page 5 and 6: 3.valg: 9/10 allel forligelig ubesl
Page 7 and 8: Petersdorf EW et al: Major-histocom
Page 9 and 10: Sygdomsspecifikke overvejelser & kr
Page 11 and 12: Non myeloablativ stamcelletransplan
Page 13 and 14: Akutte Leukæmier ALL hos voksne AL
Page 15 and 16: En metaanalyse af 7 studier, hvor a
Page 17 and 18: Højrisikofaktorer • Fænotype: N
Page 19 and 20: Kemoterapi Hoelzer, D.F (1993). The
Page 21 and 22: unrelated transplant in first compl
Page 23 and 24: ALL hos børn 5% blaster i knoglema
Page 25 and 26: i det nordamerikanske register, af
Page 27 and 28: Risikogrupper for AML i 1. CR Lavri
Page 29 and 30: Autolog KMT Litteraturen på områd
Page 31 and 32: Gale, R.P., Horowitz, M.M., Weiner,
Page 33 and 34: myelogenous leukemia in first compl
Page 35 and 36: AML hos børn
Page 37 and 38: Eapen M, Rubinstein P, Zhang MJ, Ca
Page 39 and 40: Point Parameter 0 0.5 1 1.5 2 Blast
Page 41 and 42: *) Specielt i denne gruppe gælder
Page 43 and 44: Kantarjian H, O'Brien S, Cortes J,
Page 45 and 46: Scott BL, Sandmaier BM, Storer B, M
Page 47 and 48: tiltagende. Patienter med RC og hø
Page 49 and 50: Donor leukocyte infusion after hema
Page 51 and 52: � Konstitutionelle symptomer, for
Page 53 and 54: Responskriterier ved CML Responstyp
Page 55: patienter, som statistisk set vil h
Page 59 and 60: LYMFOMER Lymfoblastært lymfom Lymf
Page 61 and 62: Der er ingen data, der indicerer at
Page 63 and 64: BURKITT'S LYMFOM Senest revideret:
Page 65 and 66: Hoelzer D, Ludwig W-D, , Thiel E et
Page 67 and 68: Der er ikke indikation for autolog
Page 69 and 70: sequential chemotherapy in poor-ris
Page 71 and 72: af immunosuppressiv beh. og DLI og
Page 73 and 74: following high-dose sequential chem
Page 75 and 76: Marginal Zone Lymfom Senest revider
Page 77 and 78: Rezvani AR, Storer B, Maris M et al
Page 79 and 80: eskriver også sammenhæng mellem i
Page 81 and 82: HCT ved refraktær sygdom (Verdonck
Page 83 and 84: transplantation for lymphoprolifera
Page 85 and 86: Perifere T-Celle Lymfomer Senest re
Page 87 and 88: Referencer: Evens AM, Gartenhaus RB
Page 89 and 90: Hodgkin Lymfom (HL) Senest revidere
Page 91 and 92: Patienter med progressiv sygdom ell
Page 93 and 94: Transplant, 12,172-183. Anderlini,P
Page 95 and 96: Allogen KMT 1. HLA-identisk søsken
Page 97 and 98: Referencer Definition Bacigalupo A,
Page 99 and 100: Paroxysmal Nocturn Haemoglobinuri,
Page 101 and 102: Autolog transplantation Myelomatose
Page 103 and 104: Cavo M, Tosi P, Zagmani E, Cellini
Page 105 and 106: Myelofibrose Idiopatisk myelofibros
Page 107 and 108:
Introduktion Retransplantation af b
Page 109 and 110:
Den samlede konklusion kunne være,
Page 111 and 112:
Thalassæmier Senest revideret nove
Page 113 and 114:
thalassæmifri overlevelse på 66%
Page 115 and 116:
Kronisk granulomatøs sygdom Senest
show all

12.5.2.30 DHS rekommandationer for KMT 2011.pdf - e-Dok

Create successful ePaper yourself

Delete template?

Save as template?